Finance entity
All 1 tracked stories fall under one category: markets. Of the tracked stories, 1 of 1 also mention Clearmind Medicine Inc., the most common co-covered peer. MEAI (5-methoxy-2-aminoindane) appears in 1 tracked Finance story from October 3, 2026. The tracked stories average 2 original sources each.
Last mentioned: 13h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. Of the tracked stories, 1 of 1 also mention Clearmind Medicine Inc., the most common co-covered peer. MEAI (5-methoxy-2-aminoindane) appears in 1 tracked Finance story from October 3, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MEAI (5-methoxy-2-aminoindane). Shared-story counts are live from our verified record — not editorial picks.
Scienture Holdings and Clearmind Medicine both execute reverse stock splits effective Oct. 5, 2026. SCNX's 1-for-25 split lifts its $0.18 stock to $4.50, while CMND's 1-for-8 split lifts $0.72 to $5.76, aiming to restore Nasdaq's $1 minimum bid.
MEAI (5-methoxy-2-aminoindane) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
